Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

GSK, Sirna in respiratory drug pact

April 10, 2006 | A version of this story appeared in Volume 84, Issue 15

In the latest show of faith in the potential of gene-silencing technology, GlaxoSmithKline has teamed up with Sirna Therapeutics to develop RNA interference-based drugs to treat respiratory diseases. GSK will make an initial payment of $12 million comprising cash and investment in Sirna stock. Sirna says it could rake in another $700 million in milestone payments and royalties on potential product sales. Sirna will supply optimized and formulated short interfering RNAs against targets generated by both companies. GSK will then conduct all preclinical and clinical development of the compounds and will commercialize any products that come out of the alliance. The deal between GSK and Sirna underscores major drug companies' growing interest in adding RNAi-based drugs to their pipelines. In February, Novartis expanded its relationship with Alnylam Pharmaceuticals to develop RNAi therapeutics for pandemic flu. Alnylam also has a relationship with Merck, while Sirna is developing eye disease drugs with Allergan.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.